@

scioDiscover - Protein Biomarker Discovery

To enable personalized medicine and diagnostic research, we need techniques to discover and validate novel and more accurate biomarkers. Our immuno-based discovery service for protein biomarkers utilizes complex antibody microarrays, spanning crucial pathway proteins for multiple diseases and secreted proteins. Our platform has been successfully applied in a variety of biomedical research studies. The platform's potential is highlighted by the successful discovery of four innovative biomarker signatures.

Our fully immuno-based workflow eliminates the need for major platform alterations, reducing attrition rates for biomarker candidates during further development. Over a decade of experience in discovering and validating protein biomarkers makes Sciomics an excellent partner for your research.

 

Biomarker Discovery for

  • Diagnosis
  • Differential Diagnosis
  • Prognosis
  • Drug Response Prediction and Therapy Stratification
  • Companion diagnostics

 

Service Features

  • Design of a suitable study layout
  • Protein extraction & purification
  • Protein quantification
  • Protein labeling using high-performance fluorescent dyes
  • Fully automated array incubation and handling 
  • Array scanning, data acquisition and spot recognition
  • Customized data analysis to fit your needs
  • Tailored study report

 

Key Advantages

  • High sensitivity (comparable to or better than ELISA)
  • High reproducibility (CV < 10%)
  • Fast turnaround time, as little as two weeks*
  • Ability to analyze various sample types
    • Serum or plasma
    • fresh-frozen tissue samples
    • Cell culture samples
    • Cerebrospinal fluid (CSF)
  • Minimum sample consumption, for instance**
    • Plasma sample: 5µl
    • Tissue: 1mg (fresh-frozen)
    • Cells: 100,000
    • CSF: 5µl
  • Investigation of human and murine samples***
  • No need for laborious depletion or fractionation of your samples
  • Verification and clinical validation without major platform change
  • Parallel verification of multiple biomarker candidates using Custom Antibody Arrays

 

Overview
Scio-Discover
    Array
Content
    Quality
Assurance
    Contact
us

 

 

Reference Customers:

Prof. Dr. Faikah Güler, Medical School Hanover, Germany

Julian Kamhieh-Milz, Charite, Berlin, Germany

 

Case Studies:

Bladder Cancer

Acute Kidney Injury

 

* depending on study design and sample size
**Minimum quantity. These values may vary depending on the sample type, study design, storage conditions. and additional parameters.
*** The antibody array is designed specifically to target human proteins. Because of the high sequence homology shared by the majority of proteins, this approach has frequently been used to study murine, rat, and ovine models effectively. [
Thorenz A. et al. (2018), Peiro J. et al. (2018), Reichman H. et al. (2019), Raquel F. et al. (2020)].

 

 

 

Our service portfolio

scioPhospho: protein profiling and phosphorylation status

scioPhospho: protein profiling and phosphorylation status

Our scioPhospho analysis combines protein expression profiling using scioDiscover with analysis of the corresponding protein's phosphorylation status. More than 1,400 proteins are analyzed in parallel, covering key pathways in diseases such as cancer, neurological disorders and organ failure.  This combination provides a comprehensive overview of signaling events and pathway activity…
Read more
scioUbi: protein profiling and ubiquitination status

scioUbi: protein profiling and ubiquitination status

Protein & ubiquitination profiling scioUbi is a high-content protein expression and ubiquitination level analysis. With scioUbi you can analyse more than 1,400 proteins in a single assay.   Features Screen…
scioDiscover - Protein Profiling on the Expression Level

scioDiscover - Protein Profiling on the Expression Level

Knowledge about protein expression levels is of utmost importance to predict toxic effects, estimate adverse effects of drug candidates and to identify new drug targets. Sciomics has a highly optimised…
scioCD - Cell Surface Marker and Cytokine Profiling

scioCD - Cell Surface Marker and Cytokine Profiling

Characterize Your Cell Type! Cell Composition Analysis in Tissue Samples CD-Marker Expression Profiles Increased Throughput at High Sensitivity Levels High Reproducibility       Our scioCD profiling service covers 349 different…
scioCyto : Cytokine Profiling

scioCyto : Cytokine Profiling

scioCyto : Cytokine profiling scioCyto is a high-content analysis service for multiplex cytokine and chemokine profiling on protein level. A great variety of samples such as plasma, tissue, cells or cell…

COVID-19 related activities and services

covid 19 portfolio web

News

New Article | Endothelial Notch1 signaling in white adipose tissue promotes cancer cachexia

| September 2023 | New Article: Endothelial Notch1 signaling in white adipose tissue promotes cancer cachexia. Sciomics supported this study by scioCyto serum analysis in a mouse cancer model.

Taylor, J., Uhl, L., Moll, I. et al. Endothelial Notch1 signaling in white adipose tissue promotes cancer cachexia. Nat Cancer 4, 1544–1560 (2023)
New Article | Rapid Diagnostic Platform for Personalized Vitamin B6 Detection in Erythrocytes

| July 2023 | New Article: Fiedler et al. developed a novel methodology for vitamin B6 diagnostics. We supported the project by the production of custom antibody microarray targeting signature human PLP-DE and testing respective samples.

New Article | Microbiota Influences Chemotherapy in Pancreatic Cancer

| February 2023 | New Article: In the study Tintelnot et al. identified a microbiota-derived metabolite that has clinical implications in the treatment of pancreatic cancer. Sciomics supported the authors by a protein profiling study of tumours derived from a mouse model upon treatment with 3-IAA and Firinox.

Tintelnot et al. Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer. Nature 615, 168-174 (2023)
New Article | Predicting a severe Covid-19 disease

| April 2023 | New Article: In a protein biomarker development project initiated by Sciomics, we have identified protein biomarker panels predicting development of a severe Covid.19  disease.

Hufnagel K., Fathi A. et al. Discovery and systematic assessment of early biomarkers that predict progression to severe COVID-19 disease. Communications Medicine 3,51 (2023)
New Sciomics Proteomics Research Blog has Launched!

Sciomics Protomics Research Blog

 

At Sciomics, we are dedicated to advancing healthcare through proteomics research. We are collaborating with research groups and big pharma, alongside our in-house biomarker research initiatives. To make this research more accessible to you, we are launching the new Sciomics science blog!

The first study we will feature was published this year in a journal in the Nature publishing group. It's a topic that affects us all. Any guesses? Stay tuned!

 

 

Testimonials

Dr. Matthew Wright

Chief Scientific Officer, Kinarus Therapeutics AG, Basel, Switzerland

"We are a small biotech company without our own wet labs. Sciomics recommended a UK CRO that performed cell culture experiments for our studies. Sciomics seamlessly coordinated the transfer of the biologic materials to their facility and performed the scioCD panel to characterize cell surface markers and cytokines in cell lines treated with our small molecule drug candidates. The Sciomics data were instrumental in supporting our IP protection strategy. Their advice was very helpful and they worked with us to extract the most out of the data. We are very satisfied and highly recommend the Sciomics platform and the team."

Product: scioCD

Kyriaki Barmpa

PhD Candidate, Developmental and Cellular Biology, Luxembourg Centre for Systems Biomedicine, University of Luxembourg

"By collaborating with Sciomics, we conducted a detailed analysis of the proteome of striatum organoids, uncovering significant differences that further assisted our research. Their communication was highly efficient, and the results were delivered promptly."

Product: scioPhospho